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Abstract Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent two
ends of a disease spectrum with shared clinical, genetic and pathological features. These include
near ubiquitous pathological inclusions of the RNA-binding protein (RBP) TDP-43, and often the
presence of a GGGGCC expansion in the C9ORF72 (C9) gene. Previously, we reported that the
sequestration of hnRNP H altered the splicing of target transcripts in C9ALS patients (Conlon et al.,
2016). Here, we show that this signature also occurs in half of 50 postmortem sporadic, non-C9
ALS/FTD brains. Furthermore, and equally surprisingly, these ‘like-C9’ brains also contained
correspondingly high amounts of insoluble TDP-43, as well as several other disease-related RBPs,
and this correlates with widespread global splicing defects. Finally, we show that the like-C9
sporadic patients, like actual C9ALS patients, were much more likely to have developed FTD. We
propose that these unexpected links between C9 and sporadic ALS/FTD define a common
mechanism in this disease spectrum.
DOI: https://doi.org/10.7554/eLife.37754.001
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that afflicts approximately 1
in 400 people worldwide (Alonso et al., 2009). Diagnosis is predicated on symptoms of motor neu-
ron (MN) loss from the primary motor cortex (upper MNs), brainstem and spinal cord (lower MNs),
which results in progressive weakness and loss of motor control, and eventually paralysis and death
(Rowland and Shneider, 2001). While predominantly a motor disorder, many ALS patients experi-
ence cognitive and behavioral changes, and ~10–15% of ALS patients meet formal criteria for a diag-
nosis of frontotemporal dementia (FTD; Lattante et al., 2015; Ling et al., 2013). FTD is a
heterogeneous condition marked by the degeneration of neurons in the frontal cortex, and patients
exhibit a range of cognitive, behavioral and language deficits (Seelaar et al., 2011).
The co-occurrence of ALS and FTD is genetically determined in some cases, most often by the
dominantly inherited C9ORF72 (C9) hexanucleotide expansion (DeJesus-Hernandez et al., 2011;
Renton et al., 2011). The presence of a single copy of expanded C9 increases sharply the chance
that an ALS-afflicted individual will be diagnosed with FTD, from 10 to ~50% (Byrne et al., 2012).
While consensus on precisely how the expanded sequence acts as a pathological unit has remained
elusive, we have shown that the repeat-containing RNA can directly sequester the RNA-binding
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protein (RBP) hnRNP H, leading to dysregulation of pre-mRNA splicing (Conlon et al., 2016). Gener-
ally, our and others’ evidence for proteinaceous aggregates, seeded by RNAs and which are prone
to undergo phase transitions (Fay et al., 2017; Jain and Vale, 2017; Schwartz et al., 2013), may
offer a bridge from aggregation - as a classical observation of neurodegenerative disease
(Ginsberg et al., 1998; Ross and Poirier, 2004) - to a biophysical mechanism at the origins of ALS/
FTD, in cases both with and without disease-associated mutations (Alberti and Hyman, 2016;
Conlon and Manley, 2017; Mackenzie et al., 2017; Murakami et al., 2015).
Histopathologic similarities also link ALS and FTD on this disease spectrum. In almost all ALS and
over half of FTD patients, the distributions of pathological cytoplasmic accumulation of the hnRNP-
like DNA/RNA binding protein TDP-43 tend to correlate with areas of neurodegeneration
(Baloh, 2011). Although the observed aggregates of TDP-43 come in several forms (Scotter et al.,
2015), translocation and nuclear clearance events are of particular interest, as they have suggested
a loss-of-function (LOF) mechanism (Vanden Broeck et al., 2014), predicted to impact mRNA proc-
essing and transport (Humphrey et al., 2017; Ling et al., 2015; Polymenidou et al., 2011;
Tollervey et al., 2011). While TDP-43 aggregation could reflect the downstream effects of cell
death rather than the cause, the existence of ALS-causing mutations in the gene that encodes TDP-
43 (TARDBP) suggests that the protein has a deterministic role in the ALS/FTD spectrum
(Scotter et al., 2015). Between the extremes of bystander and instigator, it is possible that changes
to TDP-43 reflect an important indicator of upstream processes that influence RBPs more
pervasively.
In all ALS/FTD cases with TDP-43 pathology, aggregation may be driven by any number of factors
that impact the protein’s ability to form stoichiometrically correct interactions with itself or with
other nuclear proteins and RNAs. For example, disease-linked changes affecting the solubility prop-
erties of other RBPs (Harrison and Shorter, 2017), including hnRNP H (Conlon et al., 2016), have
the potential to affect solubility of RBPs they interact with, like TDP-43 (Freibaum et al., 2010;
Ling et al., 2010), although whether this occurs in ALS/FTD patient brains is unknown. Extending
this idea, downstream changes to the transcriptome, particularly splicing patterns, may result from
combinatorial deficiencies of several RBPs (Huelga et al., 2012; Mohagheghi et al., 2016), making
it difficult to pinpoint the initiating event or distinguish specific effects of TDP-43 LOF.
In this study, we have investigated whether the biochemical ‘signature’ we described previously
for C9ALS might extend to a broader spectrum of ALS/FTD patients. For this, we analyzed splicing
and RBP solubility in 50 postmortem human brains from patients with sporadic ALS, FTD with motor
neuron disease (MND) and ALS-FTD (collectively, sALS/FTD), all of which were negative for known
disease mutations, including C9. Unexpectedly, we identified splicing dysregulation of known hnRNP
H targets (Conlon et al., 2016) in a large fraction of patients, and used the extent of splicing dysre-
gulation to divide the patients into two groups, like-control and like-C9. Notably, we found that the
like-C9 patient brains also had higher amounts of insoluble hnRNP H, the amount of which directly
correlated with the magnitude of splicing dysregulation. Importantly, several other abundant RBPs
linked to ALS, including TDP-43, showed the same patterns of insolubility as hnRNP H. Consistent
with this, we found pervasive splicing dysregulation genome wide in like-C9 brains. Intriguingly, the
like-control cases with lowest hnRNP H/TDP-43 insolubility displayed almost no splicing dysregula-
tion, despite the ubiquitous presence of histopathological TDP-43 inclusions. Finally, and impor-
tantly, we show that like-C9 patients, similar to actual C9ALS patients, were much more prone to
develop dementia than were like-control patients. Together, our data define unanticipated biochem-
ical similarities between a large fraction of sALS/FTD cases and C9ALS/FTD, suggesting a common
mechanism underlying disease pathogenesis.
Results
Patient stratification based on graded inclusion of hnRNP H-regulated
exons
C9 expansion is the most common known cause of ALS/FTD. However, a large majority of cases,
especially amongst the 90% that are sporadic in origin, are of unknown etiology. When initially
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characterizing hnRNP H-dependent splicing events, we compared C9ALS/FTD patients to neurologi-
cal controls and SOD1 ALS (not believed to proceed through a mechanism of RBP dysfunction or
aggregation; Ling et al., 2013), but not to sALS/FTD (Conlon et al., 2016). Indeed, sALS/FTD is a
mechanistic unknown and may constitute a wide range of molecular subtypes. Given that TDP-43
and hnRNP H appear to interact (Appocher et al., 2017; Ling et al., 2010; Sephton et al., 2011) in
a manner that is largely RNA dependent (Freibaum et al., 2010), it is reasonable to speculate that
changes in RNA binding and/or solubility of one might impact the other, leading to more complex
patterns of splicing dysregulation.
We first set out to determine whether splicing patterns specific to C9ALS/FTD could be distin-
guished from those related to ALS/FTD more generally. To do this, we initially analyzed whether
sALS/FTD patients display splicing changes similar to those we described in C9 patients
(Conlon et al., 2016) (Figure 1a). Specifically, we measured alternative exon inclusion by 32P-RT-
PCR of oligo(dT)-selected RNA samples purified from post-mortem cerebellum from 50 sporadic
patients: 32 classified as ALS (without cognitive/behavioral involvement), seven as ALS-FTD (symp-
toms of both disorders during the patient’s life), and 11 as FTD with motor neuron disease (FTD-
MND) defined by a lack of clinical ALS symptoms yet the presence of pathological MN degeneration
at autopsy. We also included two patients carrying pathogenic SOD1 variants, and four patients car-
rying C9 repeat expansions, for a total of 56 cases (Supplementary file 1A).
To assay hnRNP H-dependent splicing changes, we selected 18 known hnRNP H target exons
that we previously found are differentially included in C9ALS/FTD compared to individuals without
neurological symptoms and SOD1 ALS controls (Figure 1a). Four of the targets were hnRNP
H-repressed exons, meaning hnRNP H normally represses inclusion when physiological levels of the
protein are high, and the other 14 were hnRNP H-enhanced exons, which respond with decreased
inclusion when hnRNP H levels are low (Figure 1b). Results obtained with two enhanced exons (from
ARRB2 and PPP1R12C) and one repressed exon (from OS9) are shown in Figure 1c–e. Representa-
tive gels for all other genes analyzed are shown in Figure 1—figure supplement 1. The data
revealed dramatic differences across many of the patient samples. We observed several patients
that consistently had the lowest levels of enhanced exon inclusion for all 14 exons, and noticed that
these same patients had the highest levels of repressed exon inclusion (e.g. boxed FTD-MND sam-
ples 9–13; Figure 1c–e). Other patients consistently displayed the opposite trend, or a milder ver-
sion of both.
We next wished to classify the patients as either having or not having hnRNP H-dependent splic-
ing changes. For this, we first averaged the percent inclusion of all the enhanced exons to define a
single composite splicing score (CSS). We then compared the CSS values of sporadics to those of a
set of neurological normal and SOD1-ALS controls, and to C9ALS/FTD patients. Interestingly, we
observed that for these same 14 exons, the controls had a very close range of values, while the C9
+ range was centered significantly lower and with a wider distribution (Figure 1f). Only a single con-
trol point deviated significantly from the mean; this point corresponds to the second SOD1-ALS
patient and is likely due to poor RNA quality. Due to the rarity of SOD1-ALS post-mortem samples,
we decided against discarding this patient. This is the only sample in the entire set where RNA qual-
ity was compromised.
We then wished to determine which, if any, of the sporadics had exon inclusion values in the
range only accessible to C9+, and not control, brains. However, the wide range of CSS values of the
C9+ group in theory made it impossible to classify a patient as C9+ or control based on a CSS simi-
lar to a control value. The converse, however, was not true: control samples had a close range of
observed values, and all the patients with significantly lowered values were disease afflicted. Thus,
we defined ‘like-control’ as any patient with a CSS within three standard deviations (SD) of the non-
ALS mean, since this range should encompass 99.7% of values within a normally distributed popula-
tion. ‘Like-C9’ was then defined as all the patients with CSS values lower than this value. These two
categories split the 50 patients into two groups of roughly equal size (Figure 1f). Comparison of
like-control (n = 24) and like-C9 (n = 26) revealed a significant difference (p<0.05) between these
two categories for each of the 18 genes, with only one exception, RPL10 (p=0.09) (Figure 1g).
We next wished to determine, for every individual hnRNP H-regulated exon we analyzed, if each
patient displayed similar relative change in inclusion values as for all the other exons. To this end, we
first re-calculated the CSS for each combination of 13 enhanced exons and plotted a best-fit line for
each gene in the case where it was excluded from the average, using each patient’s percent exon
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Figure 1. Patient stratification into like-control and like-C9 groups by aberrant splicing of known hnRNP H-target exons. (a) List of hnRNP H target
exons, separated into enhanced and repressed categories. (b) (Top) Simplified diagram of enhanced and repressed exons with relative binding of
hnRNP H (H1). (Bottom) Depiction of expected product when H1 levels are at normal physiological levels (above dashed line) or low (hnRNP H
deficient; below dashed line). (c–e) Representative PCR gels of all patient samples for two enhanced exons (ARRB2 and PPP1R12C) and one repressed
Figure 1 continued on next page
Conlon et al. eLife 2018;7:e37754. DOI: https://doi.org/10.7554/eLife.37754 4 of 27
Research advance Biochemistry and Chemical Biology Human Biology and Medicine
inclusion value for that gene as a Y-coordinate. Indeed, we found that each individual gene followed
the trend of the patients’ average CSS (Figure 2a; simplified to show three best- and one worst-fit
lines, all others are shown in Figure 2—figure supplement 1), with the same patients consistently
showing the most severe changes, and others consistently showing the most mild. Some genes had
extremely good fit to a linear model (GABBR1, r-square = 0.90, ARRB2, r-square = 0.88), while
others displayed the trend without as good a fit (PAN2, r-square = 0.40). We also averaged the four
hnRNP H repressed exons, and plotted this value as a Y coordinate (Figure 2b). As expected, the
patients with the lowest values of hnRNP H-enhanced exon CSS had the highest levels of average
repressed exon inclusion, as the data fit well to an inverse linear relationship (r-square = 0.75).
Like-C9 sALS/FTD display increased hnRNP H insolubility
The above results defined a cohort of patients that displayed graded splicing dysregulation similar
to what we observed in C9ALS patients. We next asked whether these patients also displayed
increased levels of sarkosyl-insoluble hnRNP H, indicative of functional sequestration (see
Conlon et al., 2016). To this end, we performed biochemical fractionation of motor cortex from all
cases where tissue was available, with two independent replicates per case (Figure 2c). While we
performed RNA analysis with cerebellum for abundance and RNA quality reasons, for fractionation
we used motor cortex as it is a primary site of disease-specific degeneration. Given the historical
range of our cohort, for some samples motor cortex was unavailable, and thus we omitted those
cases from our analysis. We then analyzed equivalent amounts of each fraction, soluble (SOL), sarko-
syl soluble (SS), and sarkosyl insoluble (SI), by Western blot (WB), and calculated the percentage of
insoluble hnRNP H in each case. Using 39 samples (18 like-control and 21 like-C9), we found that the
average percent insoluble hnRNP H was 69.2 in like-C9s, and 38.9 in like-control, or 1.78 times
higher in like-C9, a highly significant increase in aggregated protein (p<0.0001) (Figure 2d; all aver-
age percent insolubility values are shown by patient in Supplementary file 1A). This enrichment
closely resembles the 1.9-fold increase we previously reported in seven C9ALS/FTD (56.1% insoluble)
compared to controls (30.0% insoluble).
We next wished to quantify the relationship, if any, between splicing severity and hnRNP H insolu-
bility. We therefore performed the same regression analysis as we did above with splicing changes,
except with percent sarkosyl-insoluble hnRNP H. We found that the general trend was for patients
with large changes in splicing to have high insoluble hnRNP H (Figure 2e; r-square = 0.58). These
observations suggest that hnRNP H is differentially sequestered, with patients showing a gradient of
decreasing soluble hnRNP H that correlates with increasing splicing dysfunction. The correspon-
dence between hnRNP H’s biochemical solubility and its predicted transcriptomic effects across dis-
tal brain regions from the same patients strongly supports the notion that this is an intrinsic, brain-
wide property of each patient. Reinforcing this view, we also examined available postmortem patho-
logical reports from 26 of the sporadic ALS/FTD patients. Significantly, 19 of these were noted to
exhibit focal loss of Purkinje neurons in the cerebellum (Supplementary file 1A), confirming that
regions of the brain undergoing robustly measured splicing defects did indeed experience neuronal
degeneration. This further justifies our choice to correlate changes measured in the cerebellum with
changes in the cortex.
Figure 1 continued
exon (OS9). Pink boxes show samples F09-F13 that consistently exhibited large magnitudes of change in inclusion. (f) Graph of CSS by group: nonALS,
C9ALS, like-control and like-C9. Each point represents the CSS of an individual patient. Red dashed line marks the cutoff of 3 standard deviations
below the control mean. Error bars are plotted to the SEM. (g) Comparison of percent exon inclusion of 18 hnRNP H-target exons between like-control
and like-C9 patient replicate values. Exons are ordered by enhanced exons (KIF1C-PCBP2) followed by repressed exons (RPL10-HNRPDL). Error bars are
plotted to the SEM. (t test p value: *=0.05, **=<0.01, ***=<0.0001, ****=<0.0001).
DOI: https://doi.org/10.7554/eLife.37754.002
The following figure supplement is available for figure 1:
Figure supplement 1. RT-PCR of hnRNP H target genes.
DOI: https://doi.org/10.7554/eLife.37754.003
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Figure 2. Differential concentration of hnRNP H due to insolubility explains graded splicing dysregulation in patient brains. (a) Linear regression of
percent exon inclusion (PEI) for each enhanced target exon compared to the average inclusion of all other enhanced exons. Clockwise from upper left:
GABBR1, DOLPP1, PAN2, ARRB2, with r-square = 0.90, 0.86, 0.40, 0.88, respectively. (b) Linear regression of percent exon inclusion for the average of
four repressed target exons compared to the average inclusion of all enhanced exons. R-square = 0.75. (c) (Upper) Diagram of biochemical
Figure 2 continued on next page
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Insolubility of hnRNP H correlates with that of the ALS-linked RBPs
TDP-43 and FUS
We previously provided evidence that the insolubility of hnRNP H in C9ALS brains was due to forma-
tion of aggregated assemblies with long, repetitive, G quadruplex-forming RNA (Conlon et al.,
2016). However, in the sporadic cases analyzed here, the source of hnRNP H insolubility/aggrega-
tion is unknown. To investigate this question, and to understand the significance of the observed
gradient of hnRNP H insolubility and splicing dysregulation, we considered the possibility that it is
related to insolubilities of other proteins with similar functions and/or domain structures. For exam-
ple, as mentioned above, TDP-43 displays histopathological evidence of cytoplasmic accumulation/
aggregation in virtually all ALS cases. Is this relevant to the biochemical insolubility we observed
with hnRNP H?
To measure insolubilities of more protein targets, including TDP-43, we selected a subset of 20
patients: the 10 most like-control and the 10 most like-C9, based on highest and lowest CSS, respec-
tively (and omitting cases where motor cortex was unavailable for fractionation) (Figure 3a). First, to
demonstrate clearly the gradient pattern of these samples for hnRNP H insolubility, we performed
simultaneous WB of all 20 samples and each of the three fractions (soluble, sarkosyl soluble and sar-
kosyl insoluble) (Figure 3b). We also performed splicing analysis of a new hnRNP H-regulated target,
ACHE (Nazim et al., 2017), further illustrating the relationship between hnRNP H insolubility and
splicing dysregulation (Figure 3c).
Having established these 20 cases as representative of the hnRNP H gradient, we used the motor
cortex fractions derived from them for WB for three other ALS/FTD-implicated hnRNPs: TDP-43,
FUS (also known as hnRNP P2), and hnRNP A1 (Figure 3d). These proteins all belong to a common
yet dynamic interactome (Markmiller et al., 2018); FUS has been reported to interact with hnRNP H
(Reber et al., 2016) and hnRNP A1 (Kim et al., 2013), while hnRNP A1 has been reported to inter-
act cooperatively with hnRNP H to modulate splice site selection (Fisette et al., 2010). Likewise,
TDP-43 was shown to interact with the structurally related hnRNP A1 to repress exon inclusion
(Buratti et al., 2005) and has also been suggested to self-associate (Polymenidou et al., 2011;
Tollervey et al., 2011) to influence a set of targets it shares with FUS (Lagier-Tourenne et al.,
2012). As a control, we also blotted for GAPDH, which seemed unlikely to be insoluble.
Strikingly, for each RBP target we found significant increases in insoluble protein in the like-C9s,
matched by significant decreases in soluble protein (Figure 3e). Indeed, no insoluble FUS could be
detected in any like-control patient, while it was present in all of the like-C9s (between
6.1 and 69.1%). Intriguingly, we found that the correlations between CSS and percentage insoluble
protein for hnRNP H, TDP-43, FUS and hnRNP A1 each fit remarkably well to a line (r-square = 0.89,
0.79. 80 and 0.90, respectively) (Figure 3f). Analysis of GAPDH revealed no insoluble protein in any
of the 20 cases (Figure 3e) confirming that insolubility of these RBPs was not due to an artifact of
fractionation or global protein insolubility in like-C9s.
The above results were unanticipated, and we therefore wished to examine properties of the
insoluble fractions further. One possibility was that the high force (180,000 x G) used to generate
the sarkosyl insoluble fractions might have resulted in an artificial enrichment of RBPs in the pellet of
some patients, and thus, the similar insolubilities of these targets may not reflect physiological inter-
actions. To examine this, we decreased the sedimentation force we used to isolate the aggregated
proteins, by separating the sarkosyl insoluble pellet at 21,000 x G for 15 min instead of 180,000 x G
Figure 2 continued
fractionation and resultant fractions. (Lower) Representative example of 6 like-control and six like-C9 samples, western blotted for actin (cortex
homogenate fraction) and hnRNP H (SOL, SS, SI). (d) Summary graph percent insoluble hnRNP H in motor cortex of like-controls versus like-C9s.
Samples for which motor cortex was unavailable were excluded from this analysis. Each point represents a single patient with replicate values. Error
bars are plotted to the SEM. (t test p value: *=0.05, **=<0.01, ***=<0.0001, ****=<0.0001). (e) Linear regression of percent insoluble hnRNP H
compared to CSS, r-square = 0.58.
DOI: https://doi.org/10.7554/eLife.37754.004
The following figure supplement is available for figure 2:
Figure supplement 1. Linear regression of hnRNP H enhanced exons.
DOI: https://doi.org/10.7554/eLife.37754.005
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Figure 3. Insolubility of hnRNP H correlates with insolubility of additional RBPs. (a) CSS scores and identifiers for 10 most like-control and 10 most like-
C9 patients for which motor cortex was available. These patients were loaded in this descending order for all parts of this figure. (b) Fractionation
(180,000 x G) of 20 sALS-FTD patients blotted for hnRNP H. SOL = soluble, SS = sarkosyl soluble and SI = sarkosyl insoluble. (c) Left: gel of ACHE
alternative splicing in 20 sALS-FTD patients, loaded in order of highest to lowest CSS. PCR products are identified at right. Right: diagram of primers
Figure 3 continued on next page
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for 30 min. We performed simultaneous fractionation and WB of the 20 cases described above, and
expanded our targets beyond hnRNP H, TDP-43, hnRNP A1 and FUS to include three additional pro-
teins that we would not expect a priori to be insoluble: Histone H3, C9ORF72 itself and splicing fac-
tor U2AF65. We also included one more target protein with broad relevance to MN disease, SMN,
which has been reported to interact with RBPs in the context of RNA transport granules (Hua and
Zhou, 2004; Thomas et al., 2011; Murakami et al., 2015).
The results of this analysis confirm and extend the observations we made with the 180,000 x G
fractionation. They support the idea that the insolubility we initially described for hnRNP H
(Figure 4a) extends to other MN disease-related proteins (Figure 4b–e), but is not a general prop-
erty of like-C9 brains. The non-disease associated proteins (Figure 4f and g) did not display any
insolubility, except for U2AF65 (Figure 4h), which had low levels of insoluble protein in six of ten
like-C9s, or 9.2% on average (Figure 4i). Intriguingly, a fraction of SMN was insoluble in all the like-
C9 cases with a range from 8.1–61.8%, or 31.1% on average, but in none of the like-controls. For
comparison, hnRNP H and hnRNP A1 were insoluble in like-C9s with a range from 16.0 to 77.5% and
29.4 to 94.7% (Figure 4i). Despite the important role of SMN in snRNP assembly, and thus in splic-
ing per se, its relatively low average insolubility in like-C9s suggests it is only partially deficient and
thus present at levels sufficient to facilitate snRNP assembly, and far higher than levels seen in SMA
(Lefebvre et al., 1997). The low levels of U2AF65 and presence of the four abundant hnRNP pro-
teins in the insoluble fraction is supportive of the like-C9s having alterations in the soluble concentra-
tion of a limited set of auxiliary splicing factors, yet maintaining sufficient concentrations of the core
factors necessary for splicing.
Reciprocal insolubilities of hnRNP H and TDP-43 reveal TDP-43 LOF is
exclusive to like-C9s
The similarity between hnRNP H and TDP-43 insolubilities in the like-C9 samples suggests that a
common process or factor may be functioning to bring about their aggregation to correspondingly
severe degrees. Supporting this idea, insolubility of each protein displayed an inverse relationship
with CSS (Figure 4j), and correlation analysis of the measured insolubilities of all these RBPs (at both
180,000 and 21,000 x G) amongst this set of 20 patients revealed highly significant correlation for
each pairwise combination (Figure 4k). The top pairwise combinations between different proteins
were between hnRNP H and TDP-43 at both 180,000 and 21,000 x G (Figure 4k; Spearman r = 0.95
for both). Supporting the idea that primary insolubility of hnRNP H can drive insolubility of these
other factors, we performed fractionation at 21,000 x G with 13 C9 patients and found similar corre-
lation between hnRNP H and TDP-43 (Spearman r = 0.71) (Figure 4—figure supplement 1).
One explanation for the similar degrees of hnRNP H and TDP-43 insolubility in the sporadic and
C9 patient brains is that they coexist in the same physical aggregates. To test this hypothesis, we
performed co-immunoprecipitation (co-IP) of hnRNP H from eluates of the sarkosyl insoluble pellets
of two like-C9 brains using a TDP-43 antibody for IP (see Materials and methods). Indeed, TDP-43
antibody successfully co-IPed hnRNP H, while a negative control antibody (FLAG-M2) or beads alone
did not (Figure 4l). These results support a reciprocal relationship between insolubility of hnRNP H
and TDP-43, whereby aggregates initially seeded by one protein can recruit the other, and vice
versa.
The possibility that a reciprocal relationship exists between hnRNP H and TDP-43 prompted us to
consider that insoluble TDP-43 is upstream of hnRNP H insolubility in like-C9s cases. Etiologically,
this is appealing, since hallmark TDP-43 histopathology is presumed to reflect underlying biochemi-
cal insolubility, and aggregation of TDP-43 into this non-functional and/or mislocalized state is often
given as a rationale for mechanistic studies that have sought evidence for TDP-43 LOF
Figure 3 continued
used and hnRNP H binding motif. (d) Fractionation shown in (b) with western blotting for the following targets (clockwise from upper-left): TDP-43, FUS,
GAPDH, hnRNP A1. Each target is shown with three panels representing SOL, SS and SI, from top to bottom. (e) Quantification of percent insoluble
protein (180,000 x G) in these 20 cases, with replicate values. Error bars are plotted to the SEM. (t test p value: *=0.05, **=<0.01, ***=<0.0001,
****=<0.0001). (f) Linear regression of percent insoluble hnRNP H, TDP-43, FUS, hnRNP A1 and GAPDH for 20 sALS-FTD patients, plotted against CSS.
R-square is listed in legend.
DOI: https://doi.org/10.7554/eLife.37754.006
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Figure 4. Like-control ALS/FTD patients have undetectable levels of insoluble RBPs after low-speed fractionation. (a–h) Low-speed (21,000 x G)
fractionation experiment with 20 patients listed in Figure 3a. Western blot hnRNP H (a), TDP-43 (b), FUS (c), hnRNP A1 (d), SMN (e), Histone H3 (f),
C9ORF72 (g), U2AF65 (h). SOL = soluble, SS = sarkosyl soluble, SI = sarkosyl insoluble. (i) Quantification of low-speed centrifugation of 20 patients with
replicate values. Error bars are plotted to the SEM. (j) Linear regression of percent insoluble protein for targets in (a–h) plotted against CSS. R-square is
Figure 4 continued on next page
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(Polymenidou et al., 2011; Lagier-Tourenne et al., 2012; Ling et al., 2015). However, our data
present a significant contradiction of this tenet, as 21,000 x G fractionation revealed TDP-43 to be,
on average, only 5.3% insoluble in the 10 like-control patients. Meanwhile, 10 patients that were on
the same clinical and pathological spectrum yet classified as like-C9 had on average almost eight
times as much insoluble TDP-43 (40.8 versus 5.3%, t test p<0.0001) (Figure 4j). Fractionation of the
same samples at 180,000 x G revealed a majority of TDP-43 to be insoluble in like-C9s (68.2%) com-
pared to a minority in like-controls (25.2%; p<0.0001; Figure 3e).
The above differential TDP-43 insolubility is in sharp contrast with the much more uniform histo-
pathology. Of the 23 sporadic cases for which we possessed data for pathological analysis by immu-
nohistochemistry with TDP-43 antibodies, only two were found to lack detectable TDP-43 inclusions
in motor regions (Supplementary file 1A). One of these, s30, was a like-control case, while the
other, F10, was the most like-C9 case (lowest CSS), and had an average of 61.8% insoluble TDP-43
based upon two measurements at 180,000 and 21,000 x G each (Figures 3f and 4i, respectively).
Conversely, case 36 had only 2.3% insoluble TDP-43 based upon two measurements at 180,000 and
21,000 x G each (Figures 3f and 4i, respectively), yet TDP-43 pathology was indeed evident
(Supplementary file 1A).
The above observation suggests that insolubility of TDP-43, as well as hnRNP H, is not related to
TDP-43 histopathology. Given that hnRNP H insolubility is correlated with splicing dysfunction of a
set of validated targets, we next asked whether TDP-43 LOF-associated splicing changes also
occurred more in the like-C9 cases than in like-controls. To assay TDP-43-dependent splicing, we
selected targets from previously published TDP-43 knockdown (KD) and CLIP studies
(Tollervey et al., 2011) and analyzed them as above by 32P RT-PCR (Figure 4—figure supplement
2). For 18 targets that produced appropriate products, we compared the percent inclusion values
from the six most like-control and six most like-C9 patients (six highest and lowest CSS, respectively).
Using a t-test for each event, and a more permissive cutoff for statistical significance (p<0.10), we
found that 10 of the 18 events displayed significant changes. Of these events, eight were as pre-
dicted consistent with the like-C9 group having lower concentrations of functional TDP-43, while the
other two displayed the opposite trend. These results suggest that TDP-43-regulated splicing events
demonstrate differential exon inclusion amongst sALS/FTD patients with TDP-43 pathology, with the
patients demonstrating biochemically insoluble TDP-43 displaying greater TDP-43 LOF.
RNA-sequencing reveals widespread splicing defects that correlate
with protein insolubility
Our investigation into splicing dysfunction initially focused specifically on hnRNP H splicing targets.
However, the results described thus far imply that the splicing changes due to decreased levels of
functional hnRNP H are complemented by shortages of other RBPs such as TDP-43. We therefore
analyzed transcriptome-wide splicing on a larger cohort of patients (28 sALS/FTD cases described
above for which hnRNP H solubility and clinical data was available and an additional 13 confirmed
C9ALS/FTD cases) using RNA-seq of RNA purified from cerebellum. As controls, we used a com-
bined group of six neurologically normal individuals and five SOD1-ALS individuals, with only two of
these 11 samples coming from our previously categorized control group (Supplementary file 1A).
The decision to include SOD1 in the control group was made because SOD1-ALS represents the
Figure 4 continued
listed. (k) Heatmap of spearman correlation coefficients for each pairwise comparison of percent insoluble protein at 180,000 or 21,000 x G (180 k
and21k, respectively). (l) Western blots of hnRNP H (top) and TDP-43 (bottom) following IP with protein A/G magnetic beads alone, TDP-43 antibody, or
control (FLAG) antibody from two patient brains (F5 and F11). The abbreviations ms and rb stand for mouse antibody and rabbit antibody, respectively.
Protein species are indicated by arrows at right, and positions of size markers are shown on the left.
DOI: https://doi.org/10.7554/eLife.37754.007
The following figure supplements are available for figure 4:
Figure supplement 1. Insoluble hnRNP H and TDP-43 correlate in C9 patient brains.
DOI: https://doi.org/10.7554/eLife.37754.008
Figure supplement 2. Quanitification of TDP-43 splicing targets.
DOI: https://doi.org/10.7554/eLife.37754.009
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only known form of ALS marked by the absence of TDP-43 (or FUS) inclusions (Mackenzie et al.,
2007).
To analyze splicing patterns globally and without bias, we regrouped the patients in a manner
independent of previously measured hnRNP H splicing. Instead, we divided the 28 sALS/FTD
patients into three groups based on clinical diagnosis and hnRNP H insolubility: ALS-hnRNP H low
insolubility (ALSlow; 7 patients), ALS-hnRNP H high insolubility (ALShigh; 13 patients) and FTD (FTD;
8 patients) (Supplementary file 1A). The first two groups consisted of patients with ALS only, and
with measured hnRNP H insolubility being below or above 50%, respectively (Figure 5a). The FTD
group consisted of those patients with clinical diagnoses of FTD. Interestingly, this group contained
the five most severely like-C9 patients. Of the 11 FTD-MND patients in our cohort that were sub-
jected to RNA-seq, only two, F3 and F7, had insolubility below 50%, and therefore were not
included in this analysis, but rather used as test cases to ascertain the predictive power of the clus-
tering with respect to insolubility. A fourth patient group consisted of C9ALS and ALS/FTD patients
(C9). The average percentage insoluble hnRNP H (180,000 x G) in each group was 26.4 in ALSlow,
59.4 in C9, 67.3 in ALShigh and 79.6 in FTD (Figure 5b). In order to rule out differential hnRNP H
levels in the cerebellum of these patients, we performed WB of tissue from 26 of the samples, and
observed that there were no changes in overall hnRNP H abundance between these groups
(Figure 5c).
We next compared differential splicing (DS) events in each of the four patient groups to the con-
trols. For this analysis, we used the annotation-free method Leafcutter (Li et al., 2018). Variations in
intron splicing were considered significant in ALS/FTD when the Percentage Spliced Index (PSI) com-
pared to control differed by more than 10% (|DPSI|  0.1) with a 10% FDR cutoff (see
Materials and methods). To confirm our assumption that neurological normal and SOD1 ALS could
be grouped as one, we compared these two groups and indeed found very few (23) detectable
splicing differences (|DPSI|  0.1). The paucity of splicing defects in these patients contrasted with
1300–1400 DS events in ALShigh and C9 groups and several thousand in the FTD group (Figure 5d;
events listed in Supplementary file 1B), with 488 events overlapping between C9, FTD and
ALShigh. Comparison of events without filtering for the magnitude of the change in PSI revealed an
even greater proportion of overlapping events between the FTD, C9 and ALShigh groups (Fig-
ure 5—figure supplement 1). As validation of our like-C9 nomenclature, with or without filtering
respectively, only 27 or 8% of all events detected in C9 were unique to that group; the remainder
were detected in ALShigh, FTD or both (like-C9 collectively). Of the remaining 73% of events that
were detected in C9 (with filtering), approximately half (48%) were shared with both other groups,
while 40 and 12% of events, respectively, were exclusively shared with FTD or ALShigh (Figure 5d).
The higher degree of overlap of C9 with FTD likely reflects the fact that with few exceptions, this
group had the largest average change in PSI for each event. Furthermore, the ALSlow group had an
insignificant number of events, even without filtering, upholding our definition of like-control for
splicing in general.
We next wished to visualize the degree of change in splicing of all events by patient. For this, we
produced heatmaps of the normalized difference in PSI for all the splicing events that differed signif-
icantly between control and any other group (|DPSI|  0.1), excluding the very large number of
events that differed exclusively between control and FTD (Figure 5d). Patients were organized
according to the above groupings, and within each group they were further arranged by increasing
hnRNP H insolubility from left to right (Figure 5e, gray-scale) to visualize the relationship between
hnRNP H insolubility and changes in splicing. To extend our analysis, we also included 23 additional
samples from C9, ALS and FTD patients that were not included in one of the groups above
(Supplementary file 1A), creating an additional group of ALS patients (ALS) not categorized as
ALSlow or ALShigh.
Hierarchical clustering of splice junctions revealed two distinct groups of events that displayed
opposite directions of normalized PSI change in the controls versus the FTDs (Figure 5e). As
expected, the ALSlow group was found to be most similar to controls, and the FTD group the most
different, reflecting the extreme ends of the insolubility spectrum. Within the C9 and ALShigh
groups, the patients displayed a gradient of patterns from low to high insolubility that generally mir-
rored the pattern of PSI from control to FTD.
We next sought to identify significant splicing changes in our dataset that best correlate with
hnRNP H insolubility. We therefore ranked events according to their correlation to insolubility
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Figure 5. hnRNP H insolubility defines patient groupings for RNA-sequencing analysis. (a) Percent insoluble hnRNP H of 28 samples in RNA-seq
analysis reveals 50% as a natural boundary between ALSlow (7 patients) and ALShigh (13 samples) samples. Percent insoluble hnRNP H of FTD patients
(8 patients) is also shown. (b) RNA-seq groups plotted by CSS and percent insoluble hnRNP H. All samples used in RNA-seq differential splicing (DS)
analysis groups are shown. (c) Western blots of hnRNP H (top) and histone H3 (middle) from whole-tissue homogenates from cerebellum of 26/28
Figure 5 continued on next page
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(Supplementary file 1C; 100 most correlated events) and plotted several. The results (Figure 6a)
demonstrate that splicing of these transcripts was, as expected, affected by variations in soluble
hnRNP H levels. Amongst these correlated events, the relationship to hnRNP H insolubility varied;
for example, splicing changes at hnRNPA3 followed a linear relationship similar to BBS, GABRG2
and CCDC136; in turn, splicing changes at hnRNPH1 occurred only when hnRNP H insolubility was
above 60%, primarily in FTD patients and some C9 patients. RIOK3 and several of the top 100 most
correlated events with hnRNP H insolubility presented exponential trends similar to hnRNPH1 splic-
ing defects. Perhaps this indicates that some events are regulated in compensatory fashions by
many factors (see below), and only undergo change in inclusion when soluble levels of multiple RBPs
are severely compromised.
Broadly, the 100 events with the highest correlation with hnRNP H insolubility displayed variable
splicing strength (intron exclusion ratios) across the cohort (Figure 6b; events listed in Figure 6—fig-
ure supplement 1), analogous to the pattern seen for all events (Figure 5e). Notably, among the
highly correlated DS events were many in transcripts encoding RBPs (Figure 6c), such as splicing
regulators, which generally followed the same pattern of PSI changes relative to insolubility in each
group (Figure 6d; heatmap events listed in Figure 6—figure supplement 2; all events listed in
Supplementary file 1D). Interestingly, several of the events found to affect RBPs (FUS exon 7,
hnRNP A1 exon 8, hnRNP D exon 7 and TIA-1 exon 5) have been the subject of intensive inquiry for
their potential roles in disease (Deshaies et al., 2018; Zhou et al., 2013) as well regulating splicing
and interactions with other hnRNPs (Gueroussov et al., 2017; Izquierdo and Valca´rcel, 2007). This
observation raises the possibility that insolubility of the disease-associated RBPs leads to specific
alterations in RNA splicing that compound defects in those same RBPs and others, thereby exacer-
bating the magnitude and extent of splicing dysregulation (see Discussion).
Beyond the RBPs, several of the DS events were consistent with possible direct roles in disease
pathology. One especially noteworthy example was the increased skipping of MAPT exon 10,
observed in C9, ALShigh and FTD (Supplementary file 1B). Alternative inclusion of this exon per-
turbs a delicate balance between 3-repeat and 4-repeat Tau, and genetic mutations in exon 10 or
the surrounding intron are a significant cause of familial FTD (Ghetti et al., 2015). While it is compel-
ling to think that specific splicing changes could drive disease pathologies, the myriad of biologically
interesting events suggests caution in attributing too much meaning to any individual event.
We next recapitulated this stratification of patient groups using hierarchical clustering. Using the
489 differential events that were common to all groups (488 common to ALShigh, C9 and FTD, and
one common to ALSlow as well) (Figure 6—figure supplement 3), patients with similar insolubility
measurements were grouped close to one another. To further support the hypothesis that all DS
events are due to insolubility and not particular clinical distinctions, clustering of patients based on
the top events that were unique to each grouping (20 from each ALShigh, C9 and FTD, and all three
events in ALSlow) also ordered the patients according to insolubility (Figure 6—figure supplement
4). Regardless of whether clustering was performed with either the most shared (Figure 6—figure
supplement 3) or the most divergent (Figure 6—figure supplement 4) events, the two groups sep-
arated by the farthest distance contained almost exactly the same patients, whereas the controls
(neurological normal and SOD1) clustered together with the patients with the lowest insolubility,
Figure 5 continued
samples used in RNA-seq analysis. Two ALShigh cases (s1 and s20) were excluded in order to fit all samples on one gel. Grayscale heatmap displays
percent insoluble hnRNP H (bottom). (d) Venn diagram of all splicing events found to be significantly different between each patient RNA-seq group
and the combined control/SOD1ALS group with PSI magnitude filtering (|DPSI|  0.1). (e) Heatmap of all events in (d), except for the 6576 events found
to have significant DS exclusively in FTD. Blue-red color scale represents Z-score for normalized PSI. Four rows above heatmap display whether each
sample was included in the groupings used for the identification of DS events, termed ’In analysis’ (black = yes, white = no), gender (pink = female,
blue = male), Patient subtype (see key), and percent insolubility hnRNP H (180,000 x G), ranging from light (low insolubility) to dark (high insolubility)
gray. Yellow is shown for cases without insolubility data. Patients are arranged by subtype, with increasing insolubility from left to right, where data is
available.
DOI: https://doi.org/10.7554/eLife.37754.010
The following figure supplement is available for figure 5:
Figure supplement 1. DS events without filtering.
DOI: https://doi.org/10.7554/eLife.37754.011
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Figure 6. Global splicing differences correlate to hnRNP H insolubility. (a) Examples of events amongst the 100-most correlated to insolubility, with
Leafcutter (LC) PSI plotted on the X-axis and insolubility (%) on the Y-axis. DS events are shown for the following genes (clockwise, from upper left):
BBS2, GABRG2, HNRNPA3, HNRNPH1, RIOK3 and CCDC136 (events listed in Supplementary file 1C). (b) Heatmap of 100 events most correlated/anti-
correlated (absolute value Spearman coefficient) with hnRNP H insolubility. Blue-red color scale represents Z-score for normalized PSI. Four rows above
Figure 6 continued on next page
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including samples not in the original ALSlow group. In summary, we conclude that widespread,
global splicing differences occur in ALS and FTD, and these can be explained by biochemical insolu-
bility of RBPs, with corresponding severity across distinct brain regions.
Like-C9 patients have a higher incidence of FTD
In the above analysis based on solubility groupings, the FTD samples were noteworthy in that they
displayed the highest hnRNP H insolubility, as well as the most numerous and acute PSI changes.
However, several sporadic and C9 ALS patients with high insolubility had similar DS patterns, imply-
ing that the excessive events were not somehow specific to the FTD clinical diagnosis, but rather the
result of exceptionally high insolubility of RBPs, which occurs at a greater rate in FTD than ALS. This
suggests a possible relationship between patients identified as like-C9 and FTD.
To determine if like C9-patients were indeed more likely to be diagnosed with FTD, we returned
to our initial assignments of like-C9 and like-control. Of the 50 patients in this analysis, 18 had symp-
toms of FTD, and were clinically diagnosed with either ALS-FTD or pure FTD, while the remaining 32
patients were diagnosed with ALS without cognitive or behavioral impairment. The majority (13/18;
72%) of the patients characterized by symptoms of FTD were like-C9, while only five of the patients
with FTD symptoms were like-control. We compared these ratios using a Fisher’s exact test, and
found that like-C9 patients were on average 3.8 times more likely to have symptoms of FTD versus
like-control patients (Figure 6e, p=0.032). Strikingly, these findings mirror what has been reported
for C9 patients, who are approximately four times more likely than the ALS population at large to
receive a diagnosis of FTD (Byrne et al., 2012). Thus we conclude that this distinction of like-C9
based upon splicing and accompanying biochemical insolubility confers clinical susceptibility to FTD,
just as occurs in authentic C9ALS patients.
Discussion
In this study, we have characterized a diverse cohort of ALS/FTD patient brains and identified a sig-
nature of graded splicing dysregulation that correlates in magnitude with insolubility of several abun-
dant and disease-relevant RBPs. Our work provides evidence that aberrant alternative splicing is a
common molecular feature of C9ALS/FTD and sporadic ALS/FTD patients, and importantly, that
these changes reflect underlying biochemical changes that manifest in RBP aggregation. A unified
vision of what causes ALS and FTD at the molecular levels has remained highly speculative despite
great advances in our understanding of the genetics that contribute to this disease spectrum
Figure 6 continued
heatmap display whether each sample was included in the groupings used for the identification of DS events, termed ’In analysis’ (black = yes,
white = no), gender (pink = female, blue = male), Patient subtype (see key), and percent insolubility hnRNP H (180,000 x G), ranging from light (low
insolubility) to dark (high insolubility) gray. Yellow is shown for cases without insolubility data. Patients are arranged by subtype, with increasing
insolubility from left to right, where data is available. (c) Gene set enrichment analysis of top 200 dysregulated splicing events correlated to hnRNP H
insolubility. (d) Heatmap of significant DS events that occur in a set of common splicing factor genes, simplified to the single most changed event per
gene (hnRNPs, SR proteins, ALS-related RBPs or SMN; events listed in Supplementary file 1D). The same four rows apply as in (b). (e) Bar graph
depicting that patients like-C9 are 3.8-times more likely to have symptoms of FTD than patients like-control (Fisher’s exact test, Odds ratio (OR) = 3.8,
p=0.032).
DOI: https://doi.org/10.7554/eLife.37754.012
The following figure supplements are available for figure 6:
Figure supplement 1. Events in Figure 6b heatmap as they appear in order.
DOI: https://doi.org/10.7554/eLife.37754.013
Figure supplement 2. Events in Figure 6d heatmap as they appear in order.
DOI: https://doi.org/10.7554/eLife.37754.014
Figure supplement 3. Heatmap of intersecting events.
DOI: https://doi.org/10.7554/eLife.37754.015
Figure supplement 4. Heatmap of subtype-specific DS events.
DOI: https://doi.org/10.7554/eLife.37754.016
Figure supplement 5. A model for a multi-RBP proteinopathy and splicing dysregulation as a common mechanism underling ALS/FTD pathogenesis.
DOI: https://doi.org/10.7554/eLife.37754.017
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(Taylor et al., 2016). Thus, our work is significant in that it provides a compelling case for the exis-
tence of a shared biochemical mechanism that occurs in ALS, FTD and ALS/FTD, and which can be
rationalized in the context of other known disease mutations and pathologies.
RNA splicing defects have previously been reported in C9ALS (Conlon et al., 2016) and sporadic
ALS/FTD (Ling et al., 2015; Prudencio et al., 2015). However, in the absence of mechanistic
insights into the origins of these defects in sporadic patients, the assumed culprit has been TDP-43
deficiency, reflecting the almost universal observation of TDP-43 histopathology
(Polymenidou et al., 2011; Lagier-Tourenne et al., 2012; Ling et al., 2015). Through stratification
of patient samples based on biochemical insolubility of hnRNP H, and by extension TDP-43, we
found that TDP-43 pathology is not sufficient to confer detectable splicing differences relative to
neurologically normal controls or SOD1 ALS patients. Thus, our data suggest a model (Figure 6—
figure supplement 5) in which TDP-43 is just one of several affected RBPs. Our finding that bio-
chemical insolubility of TDP-43 correlates with splicing defects as well as with insolubility of several
other RBPs casts doubt on the TDP-43-centric view of ALS (Lagier-Tourenne and Cleveland, 2009;
Scotter et al., 2015). Given the decoupling of visible pathology from biochemical insolubility, with
only the latter correlated with splicing dysregulation, our results strongly suggest that ALS/FTD
should be considered a multiRBP proteinopathy rather than a TDP-43 proteinopathy.
The fact that approximately half of sporadic ALS/FTD patient brains do not display significant
splicing defects or insoluble protein seemingly contradicts our assertion that this is the common
mechanism underlying disease. One possibility is that an entirely distinct mechanism drives neurode-
generation in these patients, perhaps one similar to SOD1ALS in which soluble hnRNP H and splicing
profiles resemble neurologically normal controls. Alternatively, the range of abnormality in sALS
patients we observed may reflect what we detected in C9ALS/FTD (Conlon et al., 2016). Specifi-
cally, some C9 patients displayed severe splicing changes, while others were indistinguishable from
normal controls. One possible explanation for this is that in both C9s and sporadic cases, some
patients display these changes only on a limited scale. For example, splicing and insolubility changes
may be confined to only the most vulnerable cell types in patients (sporadic and C9) that were mod-
estly different from control. As a result, changes in splicing or solubility that occur in a minority sub-
population of cells could be diluted in bulk studies by more numerous transcripts derived from
unaffected cell types. A future goal will be to try to investigate whether such specific splicing events
indeed exist that are unique or disproportionately relevant to affected neuronal populations.
Another interpretation of our data is that detectable splicing changes and highly insoluble protein
levels may only become evident in the later stages of a progressive coalescence of RBPs (Lin et al.,
2015; Murakami et al., 2015; Patel et al., 2015). In such a model, splicing changes, while undoubt-
edly contributory, may not be the sole, or critical, event driving disease onset or progression, but
rather a consequence of perturbations in the equilibrium of soluble versus aggregated RBPs (Fig-
ure 6—figure supplement 5). Many studies of ALS/FTD disease mechanisms have focused on a
complex equilibrium between differentially concentrated RBPs in physically distinct phases. Impor-
tantly, many factors, including mutations known to cause disease (Kim et al., 2013;
Murakami et al., 2015; Patel et al., 2015; Martinez et al., 2016; Fay et al., 2017;
Mackenzie et al., 2017), are capable of influencing the balance between protein concentrations in
each phase over time (Ramaswami et al., 2013). Our model (Figure 6—figure supplement 5) pro-
poses that all ALS/FTD patients fall at varying points beyond a hypothetical ‘toxicity boundary’ that
would be analogous to the phase boundaries that describe physiological granule formation
(Weber and Brangwynne, 2012; Elbaum-Garfinkle et al., 2015), only unidirectional. The magnitude
of this imbalance, or position past a theoretical tipping point, would thus be related to increased
abundance of biochemically insoluble protein and decreased levels of functional RBPs, leading to
aberrant splicing.
The above model depicts RBP insolubility as lying upstream of splicing defects. However, it is
worth considering the possibility that splicing changes lead to, or at least contribute to, insolubility.
Notably, two events found to affect the RBPs hnRNP D and hnRNP A1 (exons 7 and 8, respectively)
have been shown to cause inclusion of glycine-tyrosine (GY)-rich intrinsically disordered regions
(IDRs) in their respective proteins (Gueroussov et al., 2017). In our analysis, we observed increased
inclusion of hnRNP D exon 7, leading to an isoform with an extended GY-rich region that makes
increased contacts with other hnRNPs, thereby potentially promoting overly stable RBP complexes.
Inclusion of hnRNP A1 exon 8 also extends its IDR, although the difference in the number of GY-
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repeats is not as strong as for hnRNP D (Gueroussov et al., 2017). Somewhat surprisingly, hnRNP
A1 exon 8 was found in our data to be more skipped as RBP insolubility increased, which seems to
contradict a recent study suggesting that reduced levels of TDP-43 promote inclusion of this exon
(Deshaies et al., 2018). In contrast, the loss of soluble FUS, which regulates its own transcript, may
explain FUS splicing defects in our data. Normally, FUS protein represses inclusion of exon 7, leading
to a FUS isoform that undergoes nonsense-mediated decay in a self-regulating loop (Zhou et al.,
2013). Thus, it may be that reduced levels of soluble FUS lead to the observed increase in exon 7
inclusion, thereby resulting in excess levels of FUS that either seed RBP aggregates or ‘pile on’ to
existing ones. Such a mechanism, whereby splicing changes affecting one or a few RBPs act as ‘driv-
ers’ of RBP aggregation, can also be envisioned for other events in our analysis, for example, hnRNP
H1, which we found undergoes differential splicing in its gly-rich IRD. Regardless of whether insolu-
bility is upstream of splicing changes, or splicing changes precipitate insolubility, these events, and
likely others, highlight how the two processes may reinforce one another in a vicious cycle, ultimately
leading to the severe insolubility/splicing dysregulation we have documented in the like-C9 ALS and
FTD cases.
If all ALS-FTD indeed converges on the same mechanism then what factors dictate the onset and
progression of disease at the clinical level? This is not straightforward, even when a known mutation
underlies disease. In the case of C9, understanding how a single genetic polymorphism can lead to
two different disorders, or a combination of the two, is perplexing. Further complicating matters,
the C9 expansion has been associated with scarce disease incidence in a wide spectrum of neurode-
generative and psychiatric conditions, including Huntington’s Disease, Parkinson’s Disease, and
Schizophrenia (Hensman Moss et al., 2014; Lesage et al., 2013; McLaughlin et al., 2017). It is
unclear if these different patterns of neuronal degeneration reflect intra-patient variation in toxic
burden across cell types/brain regions (Mackenzie et al., 2014), or if particular cell-types have inher-
ently lower tolerance to toxic threats that are uniform across an individual (Nijssen et al., 2017). It
may be that a combination of burden mosaicism and varying toxicity thresholds of distinct cell types
converge to affect disease progression, such that mutation alone cannot predict the disease course
of a given individual (Van Mossevelde et al., 2017). In our C9 model, these hypothetical burdens
may be manifested and/or enhanced by transcriptional activity of the expanded locus (Liu et al.,
2014), heightened ratio of aggregated to soluble hnRNP H, and increasingly severe splicing
changes. For sALS/FTD, we know the latter two occur, but as of yet, what triggers this remains a
mystery.
The variation in disease severity implied in our model also suggests a natural progression of dis-
ease from ALS to FTD along this clinical spectrum. Our results suggest that FTD patients are further
past this hypothetical boundary than are patients with pure ALS, as reflected by the highest values
of RBP insolubility, and most global splicing changes. Given that all of the patients in our cohort with
FTD also displayed MN loss, but not all ALS patients displayed signs of frontal cortex deterioration,
we propose that the distinct neuronal populations affected by this disease spectrum have differential
vulnerabilities to the alterations in granule dynamics that define the toxicity boundary. The height-
ened sensitivity of spinal MNs implied by this gradient parallels what is known about SMA, a disease
where subtle alterations in the concentration of the protein SMN cause highly specific degeneration
of spinal MNs, with further increasing deficiency in SMN resulting in wider systemic dysfunction
(Tu et al., 2017). In both cases, disease mechanisms have been suggested to converge on perturba-
tions of granule dynamics (Zhang et al., 2006; Shan et al., 2010; Ishihara et al., 2013) and RNA
splicing (Tsuiji et al., 2013; Zhang et al., 2008).
The observation that defects in mRNA splicing may have relevance to ALS was made 20 years
ago, through examination of the disease-relevant EAAT2 gene product (Lin et al., 1998). In retro-
spect, our findings shed new light on the observation that splicing changes could be found region-
specifically, and in most, but not all, sporadic patients. In addition to providing a potential mechanis-
tic basis for this observation, our data can fit it into a broader mechanistic context that correlates
changes in mRNA splicing with changes in RBP solubility. While the ubiquity of TDP-43 pathology to
ALS/FTD, and the protein’s known roles in RNA processing, brought RNA biology to the forefront of
research on these diseases, we now conclude that RNA processing defects are not simply correlated
to visible pathology. Nonetheless, the microscopically invisible fluctuations in RBP concentration that
we have described biochemically imply that this complex spectrum of disease states can be reached
through many paths, some genetically mediated, some potentially driven by environment and
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experience. Our discovery that a large fraction of all ALS/FTD is characterized by a ‘like-C9’ signa-
ture and reflects a ‘multiRBP proteinopathy’ thus provides a unifying theme for these complex and
lethal diseases.
Materials and methods
Key resources table
Reagent type (species)
or resource Designation Source or reference Identifiers Additional information
Biological sample
(human)
Patient brains samples NA All identifiers are provided
in Supplementary file 1A
Antibody hnRNP H (rabbit) Bethyl, A300-511
Antibody hnRNP H (rabbit, Co-IP) ThermoFisher, PA5-27610
Antibody TDP-43 (rabbit) Proteintech, 10782–2-AP
Antibody TDP-43 human specific
(mouse)
Proteintech, 60019–2-Ig
Antibody hnRNP A1 (mouse) Sigma, 4B10
Antibody FUS (mouse) Santa Cruz Biotechnologies, H-6
Antibody GAPDH (rabbit) Sigma, G9545
Antibody U2AF65 (mouse) Sigma, U4758
Antibody SMN (mouse) Sigma, S2944
Antibody Histone H3 (rabbit) Abcam, 1791
Antibody FLAG-M2 (mouse) Sigma, F1804
Antibody Actin (rabbit) Sigma, A2066
Antibody C9ORF72 (rabbit) Novus, 1086CGP
Software, algorithm Leafcutter Li et al. (2018)
Acquisition of patient materials
Human patient brains were donated for research by next of kin. Samples were acquired from the
New York Brain Bank. C9 expansion testing was performed by repeat-primed PCR in the Clinical
Pathology lab of Columbia University Medical Center. All available clinical and pathological records
were collected and used to summarize patient demographics and disease features. Additional sam-
ples were obtained by the New York Genome Center as part of the Target ALS post-mortem core.
RT-PCR
Total RNA was extracted from patient cerebellum, polyA selected, reverse-transcribed, and ampli-
fied by 32P-PCR for 33 cycles with established primers as previously described (Conlon et al., 2016).
Products were electrophoresed side-by-side on 6% native PAGE and exposed to phosphor. Percent
inclusions were measured using ImageQuant, and replicate data from two independent RNA extrac-
tions per sample were graphed and analyzed with Graphpad for Prism. All primer sequences for
hnRNP H (Conlon et al., 2016) and TDP-43 (Tollervey et al., 2011) targets were previously pub-
lished. Primer sequences (5’ 3’) for ACHE are as follows: 4F: GAACCGCTTCCTCCCCAAATT; 5aR:
CAGCCTCCCCATGGGTGAA; 5bR: GTGGAACTCGGCCTTCCACT.
Biochemical fractionation
Biochemical fractionation using Sarkosyl-containing buffers was performed as previously described
(Conlon et al., 2016), with 21,000 x g centrifugation (15 minutes) substituted for 180,000
x g (30 minutes) where indicated. All three fractions, soluble, sarkosyl soluble and sarkosyl insoluble,
were western blotted simultaneously, and the band intensities of each fraction were quantified using
ImageJ from a single exposure.
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Western blotting
Western blotting was performed as previously described (Conlon et al., 2016). Antibodies used in
include Actin (Sigma, A2066), hnRNP H (Bethyl, A300-511), TDP-43 (Proteintech, 10782–2-AP), FUS
(Santa Cruz Biotechnologies, H-6), GAPDH (Sigma, G9545), hnRNP A1 (Sigma, 4B10), Histone H3
(Abcam, 1791), SMN (Sigma, S2944), U2AF65 (Sigma, U4758), C9ORF72 (Novus, 1086CGP), FLAG-
M2 (Sigma, F1804). All primary antibodies were incubated in Pierce Protein-free blocking buffer.
Co-Immunoprecipitation
Fractionation was performed as described (Conlon et al., 2016) with the following exceptions: after
the 180,000 x g centrifugation, the insoluble pellet was washed briefly with milliQ water, then incu-
bated in 20 mM Tris, 100 mM KCl (supplemented with 10 mM phenylmethylsulfonyl fluoride (PMSF)
and 10 mg/ml each of aprotinin, leupeptin and pepstatin [a/l/p]) equal to 5% the volume of the Sark-
sosyl soluble-fraction. The pellet was incubated with rotation for 24 hr at 4˚C, then centrifuged
briefly at 5000 x g. One microliter of elutant (without debris) was diluted into a final volume of 50 ml
IP buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% NP-40, 10% glycerol with 10 mM PMSF and 10
mg/ml each of a/l/p) with either 0.5 ug TDP-43 antibody (Proteintech, 60019–2-Ig), 0.5 mg FLAG-M2
antibody (Sigma) or nothing, and incubated at 4˚C for 60–100 min with rotation. One ul of input was
removed and stored at 4˚C. Protein A/G beads (Pierce; 10 ml per sample) were washed three times
with 1 mL IP buffer, the resuspended in 25 ml IP buffer. Beads were then mixed with the 50 ml sam-
ple, and incubated for 16–24 hr at 4˚C with rotation. Supernatants were separated from beads on a
magnetic stand, and beads were washed three times with 1 mL high-salt IP buffer (50 mM Tris pH
7.5, 500 mM NaCl, 0.5% NP-40, 10% glycerol with 10 mM PMSF and 10 mg/ml each of a/l/p), with 5
min rotation at 4˚C with each wash. Beads were centrifuged briefly (<10 s) at 500 x g after the third
wash, and residual liquid was fully removed. Beads were eluted for 5–8 min with 100 mM glycine, pH
2.0 at room temperature, then immediately neutralized with 100 mM Tris pH 10.0. The eluent was
mixed with 4X SDS sample buffer, boiled, electrophoresed by 8% SDS-PAGE, and western blotted
with hnRNP H (ThermoFisher, PA5-27610) and TDP-43 (Proteintech, 10782–2-AP) antibodies.
RNA-sequencing
Total RNA was extracted from flash-frozen post-mortem cerebellum tissue in Trizol/Chloroform and
purified using a Qiagen RNeasy minikit column. Starting form 500 ng total RNA input, rRNA deple-
tion and library preparation were performed according to the manufacturer’s conditions using the
KAPA Stranded RNA-Seq Kit with RiboErase and unique Illumina-compatible indexes (NEXTflex
RNA-seq Barcodes, BioScientific). Multiplexed libraries 550 bp in length were sequenced PE 125
(Illumina HiSeq 2500).
Computational methods
Forty to sixty million filtered reads were aligned to GRCh38 using STAR (2.5.2a) (Dobin and Gin-
geras, 2015). Differential splicing analysis was performed using the LeafCutter annotation-free algo-
rithm (Li et al., 2018). The package was implemented with default parameter settings per the
author’s recommendations: at least 50 split reads must support the cluster with introns up to 500 kb.
Only clusters with p-adjusted <0.1 were considered for further analysis (a lower p-adjusted cutoff
proved to be too stringent, with no significant clusters listing for the ALSlow analysis). We used gen-
der as an additional co-variate to prevent events attributable to gender from cluttering the results.
Variations in intron splicing were considered significant in ALS/FTD when the Percentage Spliced
Index (PSI) compared to control differed by more than 10% (|DPSI|  0.1) with 10% FDR cutoff. Dif-
ferential splicing events were then mapped to gene names to identify events of interest using Gen-
code version 25.
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